Bonjour Europe

European Commission Greenlights Keytruda and Padcev Combo as First-Line Treatment for Advanced Urothelial Carcinoma | iPharmaCenter

European Commission Expands Approval for GSK's Arexvy, the First RSV Vaccine for Adults Aged 50-59 at Increased Risk | iPharmaCenter

Roche aims PNH market with SC PiaSky, aims to target AZ's Ultomiris market | iPharmaCenter

European Union Approves Ordspono for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | iPharmaCenter

Leqembi (lecanemab) Approved in Great Britain for Early-Stage Alzheimer's Disease | iPharmaCenter

The European Commission Grants Approval for Tepkinly for a New Indication in Treating Relapsed/Refractory Follicular Lymphoma in Adults | iPharmaCenter

Dupixent (Dupilumab) Gains EU Approval as the First Targeted Therapy for COPD

Committee for Medicinal Products for Human Use | CHMP Positive Opinion | June | Europe Drug Approvals | 2024 | iPharmaCenter

European Commission Approves Roche's Alecensa as First Targeted Adjuvant Therapy for Early-Stage ALK-Positive Lung Cancer | 2024 | iPharmaCenter

Biogen Gains European Commission Approval for QALSODY (tofersen), a Novel Therapy for a Rare Genetic Form of ALS | EMA Drug Approvals | 2024 | iPharmaCenter

EMA Drug Approvals | Europe drug approvals | 2024 | iPharmaCenter

EMA Drug Approvals - CHMP Positive Opinions | March 2024 | iPharmaCenter

CHMP Positive Opinions | February | 2024 | iPharmaCenter

Medicines and Healthcare products Regulatory Agency | UK Drug approvals | News | iPharmaCenter

EMA Drug Approvals | CHMP Positive Opinions in October 2023 | Europe drug approvals | iPharmaCenter

Drug approvals in Europe| EMA drug approvals | 2023 |European Commission News| iPharmaCenter

CHMP Positive Opinions | EMA Drug Approvals | European Commission | 2023 | iPharmaCenter

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

Medicines and Healthcare products Regulatory Agency | News | 2023 Approvals | iPharmaCenter

2022 | CHMP Positive Opinions | EMA Drug Approvals | European Commission | Pharma | News

Drug approvals in Europe| EMA drug approvals in 2022 |European Commission News| iPharmaCenter

France healthcare News | HAS Sante | COVID 19 | Drug approvals | iPharmaCenter

COVID19 drug updates | FDA EMA approved COVID19 drugs

Opdualag was approved for unresectable/metastatic melanoma | LAG-3 inhibitors | Mode of action

European Commission approved Scemblix for chronic myeloid leukemia | iPharmaCenter

Roche’s Polivy was approved as first-line therapy for patients with DLBCL.

Germany HTA News | IQWIG and G-BA assessment news | Germany Pharma News

European Commission approved Roche's and Celltrion's monoclonal antibodies for COVID19

European Commission approved Benlysta for active lupus nephritis

France COVID-19 Updates | COVID-19 News in Europe

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

CHMP Opinions | EMA drug approvals

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphoma

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

ESMO 2020

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

JULY 2020 CHMP POSITIVE OPINION

European Commission approved Lynparza for metastatic pancreatic cancer

Gilead’s Veklury received conditional marketing authorization from the European Commission

European Commission approved Janssen's Ebola vaccine

GSK and Clover Biopharmaceuticals begins COVID-19 vaccine Phase 1 clinical trial

Governments and other organizations raised US$ 8.8 billion at Global Vaccine Summit

#EULAR2020

Sanofi’s Sarclisa approved in Europe for relapsed and refractory multiple myeloma

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients